D-dimer levels in combination with residual venous obstruction and the risk of recurrence after anticoagulation withdrawal for a first idiopathic deep vein thrombosis

Summary

We assessed the predictive value of D-dimer levels in combination with residual venous obstruction (RVO) for recurrent venous thromboembolism (VTE) in a prospective cohort of outpatients after oral anticoagulant therapy (OAT) suspension for a first episode of idiopathic proximal deep vein thrombosis of the lower limbs during a 2-year follow-up. Patients (n=400) were enrolled on the day of OAT suspension when RVO was determined by compression ultrasonography (present in 48.6% of patients). D-dimer (cut-off value: 500 ng/mL) was measured 30±10 days afterwards (abnormal in 56.4% of patients). The overall recurrence rate was 16.7% (67/400; 95% confidence intervals - CI -:13–21%). The multivariate hazard ratio (HR) for recurrence was 3.32 (95% CI:1.78–6.75; p > 0.0001) for abnormal D-dimer compared to normal D-dimer and 1.2 (95% CI:0.72–2.07; p>0.05) for RVO compared to absent RVO. The recurrence rate was 5.7% (95% CI:2–13%) and 10.4% (95% CI:6–18%), respectively, for normal D-dimer either without or with RVO, 22.9% (95% CI:14–33%) and 25.9% (95% CI: 18–35%), respectively, for abnormal D-dimer, either without or with RVO. When compared with normal D-dimer without RVO, the multivariate HR for recurrence was similar for abnormal D-dimer either with RVO (4.76 – 95% CI:1.78–12.8) or without RVO (4.3–95%:1.56–11.88). Abnormal D-dimer at one month after OAT withdrawal is an independent risk factor for recurrent VTE, while RVO at the time of OAT withdrawal, either with normal or abnormal D-dimer after one month, does not influence the risk of recurrence.

Keywords

Venous thromboembolism - vitamin K antagonists - thrombosis - hypercoagulability - thrombophilia

• References

• 1 Hirsh J, Lee A. How we diagnose and treat deep vein thrombosis. Blood 2002; 99: 3102-10.
• 2 Büller H R, Agnelli G, Hull RD. et al. Antithrombotic therapy for venous thromboembolic disease. The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004; 126: 401S-428S.
• 3 Hirsh J, Kearon C, Ginsberg J. Duration of anticoagulant therapy after first episode of venous thrombosis in patients with inherited thrombophilia. Arch Intern Med 1997; 157: 2174-7.
• 4 Research Committee of the British Thoracic Society. Optimum duration of anticoagulation for deepvein thrombosis and pulmonary embolism. Lancet 1992; 340: 873-6.
• 5 Levine MN, Hirsh J, Gent M. et al. Optimal duration of oral anticoagulant therapy: a randomized trial comparing four weeks with three months of warfarin in patients with proximal deep vein thrombosis. Thromb Haemost 1995; 74: 606-11.
• 6 Schulman S, Rhedin AS, Lindmarker P. et al. A comparison of six weeks with six months of oral anticoagulant therapy after a first episode of venous thromboembolism. N Engl J Med 1995; 332: 1661-5.
• 7 Kearon C, Gent M, Hirsh J. et al. A comparison of three months of anticoagulation with extended anticoagulation for a first episode of idiopathic venous thromboembolism. N Engl J Med 1999; 340: 901-7.
• 8 Linkins LA, Choi PO, Douketis JD. Clinical impact of bleeding in patients taking oral anticoagulant therapy for venous thrombomebolism. Ann Int Med 2003; 139: 893-900.
• 9 Agnelli G, Prandoni P, Santamaria MG. et al. Three months versus one year of oral anticoagulant therapy for idiopathic deep venous thrombosis. N Eng J Med 2001; 345: 165-9.
• 10 Agnelli G, Prandoni P, Becattini C. et al for the Warfarin Optimal Duration Italian Trial Investigators. Extended Oral Anticoagulant Therapy after a First Episode of Pulmonary Embolism. Ann Intern Med 2003; 139: 19-25.
• 11 Pinede L, Ninet J, Duhaut P. et al. Comparison of 3 and 6 months of oral anticoagulant therapy after a first episode of proximal deep vein thrombosis or pulmonary embolism and comparison of 6 and 12 weeks of therapy after isolated calf-vein thrombosis. Circulation 2001; 103: 2453-60.
• 12 Piovella F, Crippa L, Barone M. et al. Normalization rates of compression ultrasonography in patients with a first episode of deep vein thrombosis of the lower limbs: association with DVT recurrence and new thrombosis. Haematologica 2002; 87: 515-22.
• 13 Prandoni P, Lensing AWA, Prins MH. et al. Residual vein thrombosis as a predictive factor of recurrent venous thromboembolism. Ann Intern Med 2002; 137: 955-60.
• 14 Palareti G, Legnani C, Cosmi B. et al. Risk of venous thromboembolic recurrence: high negative predictive value of D-dimer performed after oral anticoagulation is stopped. Thromb Haemost 2002; 87: 7-12.
• 15 Eichinger S, Minar E, Bialonczyk C. et al. D- dimer levels and risk of recurrent venous thromboembolism. JAMA 2003; 290: 1071-4.
• 16 Bauer KA. The thrombophilias: well-defined risk factors with uncertain therapeutic implications. Ann Int Med 2001; 135: 367-73.
• 17 Simioni P. Risk of recurrent venous thromboembolism and thrombophilia: does discrepancy make complexity and vice versa?. J Thromb Haemost 2003; 1: 16-18.
• 18 Palareti G, Legnani C, Cosmi B. et al. Predictive value of D-dimer test for recurrent venous thromboembolism after anticoagulation withdrawal in subjects with a previous idiopathic event and in carriers of congenital thrombophilia. Circulation 2003; 108: 313-8.
• 19 Prandoni P, Cogo A, Bernardi E. et al. A simple ultrasound approach for detection of recurrent proximal- vein thrombosis. Circulation 1993; 88: 1730-5.
• 20 Fedullo PF, Tapson VF. The evaluation of suspected pulmonary embolism. N Engl J Med 2003; 349: 1247-56.
• 21 Kearon C. Diagnosis of pulmonary embolism. CMAJ 2003; 168: 183-92.
• 22 Franzeck UK, Schalch I, Jager KA. et al. Prospective 12-year follow-up study of clinical and hemodinamic sequelae after deep vein thrombosis in low-risk patients (Zürich study). Circulation 1996; 93: 74-9.
• 23 O’Shaughnessy AM, Fitzgerald DE. Natural history of proximal deep vein thrombosis assessed by duplex ultrasound. Int Angiol 1997; 16: 45-9.
• 24 Emmerich J, Fiessinger JN. Residual venous thrombosis and recurrent venous thromboembolism. Ann Int Med 2003; 139: 303-4.